Extinction of west nile virus by favipiravir through lethal mutagenesis

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Escribano Romero, Estela ^a   De Oya, Nereida Jiménez ^a   Domingo, Esteban ^b,c   Saiza, Juan Carlos ^a  

^a INIA   (Spain)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiviral agents; Favipiravir; Flavivirus; Lethal mutagenesis; West Nile virus

Indexed keywords

FAVIPIRAVIR; VIRUS RNA; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CC50; CONTROLLED STUDY; FLAVIVIRIDAE INFECTION; IC50; IN VITRO STUDY; MUTAGENESIS; MUTAGENIC ACTIVITY; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; VERO CELL LINE; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS TITRATION; WEST NILE VIRUS; ANIMAL; CHLOROCEBUS AETHIOPS; DOSE RESPONSE; DRUG EFFECT; GENETICS; PATHOGENICITY;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; MUTAGENESIS; PYRAZINES; VERO CELLS; WEST NILE VIRUS;

EID: 85032491122     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01400-17     Document Type: Article

References (54)

1. Martin-Acebes MA, Saiz JC. 2012. West Nile virus: a re-emerging pathogen revisited. World J Virol 1:51–70. https://doi.org/10.5501/wjv.v1.i2.51.
2. Sejvar JJ. 2014. Clinical manifestations and outcomes of West Nile virus infection. Viruses 6:606–623. https://doi.org/10.3390/v6020606.
3. Kok WM. 2016. New developments in flavivirus drug discovery. Expert Opin Drug Discov 11:433–445. https://doi.org/10.1517/17460441.2016.1160887.
4. Hamer GL, Kitron UD, Goldberg TL, Brawn JD, Loss SR, Ruiz MO, Hayes DB, Walker ED. 2009. Host selection by Culex pipiens mosquitoes and West Nile virus amplification. Am J Trop Med Hyg 80:268–278.
5. Zhang S, Vogt MR, Oliphant T, Engle M, Bovshik EI, Diamond MS, Beasley DW. 2009. Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J Infect Dis 200:202–205. https://doi.org/10.1086/599794.
6. Borderia AV, Rozen-Gagnon K, Vignuzzi M. 2016. Fidelity variants and RNA quasispecies. Curr Top Microbiol Immunol 392:303–322. https://doi.org/10.1007/82_2015_483.
7. Van Slyke GA, Arnold JJ, Lugo AJ, Griesemer SB, Moustafa IM, Kramer LD, Cameron CE, Ciota AT. 2015. Sequence-specific fidelity alterations associated with West Nile virus attenuation in mosquitoes. PLoS Pathog 11:e1005009. https://doi.org/10.1371/journal.ppat.1005009.
8. Perales C, Domingo E. 2016. Antiviral strategies based on lethal mutagenesis and error threshold. Curr Top Microbiol Immunol 392:323–339. https://doi.org/10.1007/82_2015_459.
9. Day CW, Smee DF, Julander JG, Yamshchikov VF, Sidwell RW, Morrey JD. 2005. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 67:38–45. https://doi.org/10.1016/j.antiviral.2005.04.002.
10. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977–981. https://doi.org/10.1128/AAC.46.4.977-981.2002.
11. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446–454. https://doi.org/10.1016/j.antiviral.2013.09.015.
12. Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y, Van Wettere A, Furuta Y, Gowen BB. 2014. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res 104:84–92. https://doi.org/10.1016/j.antiviral.2014.01.016.
13. Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, Sato Y, Suzuki T, Nagata N, Hasegawa H, Kawai Y, Uda A, Morikawa S, Shimojima M, Watanabe H, Saijo M. 2016. Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocy-topenia syndrome virus. mSphere 1:e00061-15. https://doi.org/10.1128/mSphere.00061-15.
14. Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. 2016. Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis. J Infect Dis 213: 1253–1261. https://doi.org/10.1093/infdis/jiv586.
15. Jochmans D, van Nieuwkoop S, Smits SL, Neyts J, Fouchier RA, van den Hoogen BG. 2016. Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters. Antimicrob Agents Chemother 60:4620–4629. https://doi.org/10.1128/AAC.00709-16.
16. Gowen BB, Juelich TL, Sefing EJ, Brasel T, Smith JK, Zhang L, Tigabu B, Hill TE, Yun T, Pietzsch C, Furuta Y, Freiberg AN. 2013. Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS Negl Trop Dis 7:e2614. https://doi.org/10.1371/journal.pntd.0002614.
17. Gowen BB, Westover JB, Sefing EJ, Van Wettere AJ, Bailey KW, Wandersee L, Komeno T, Furuta Y. 2017. Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antiviral Res 145:131–135. https://doi.org/10.1016/j.antiviral.2017.07.019.
18. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51:3168–3176. https://doi.org/10.1128/AAC.00356-07.
19. Gowen BB, Wong MH, Jung KH, Smee DF, Morrey JD, Furuta Y. 2010. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebo-virus disease models. Antiviral Res 86:121–127. https://doi.org/10.1016/ j.antiviral.2009.10.015.
20. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB. 2011. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 55:782–787. https://doi.org/10.1128/AAC.01219-10.
21. Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB. 2011. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl Trop Dis 5:e1342. https://doi.org/10.1371/journal.pntd.0001342.
22. Oestereich L, Rieger T, Ludtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Munoz-Fontela C, Gunther S. 2016. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 213:934–938. https://doi.org/10.1093/infdis/jiv522.
23. Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, Gowen BB. 2013. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother 57:4673–4680. https://doi.org/10.1128/AAC.00886-13.
24. Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB. 2015. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 5:14775. https://doi.org/10.1038/srep14775.
25. Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB. 2016. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62–68. https://doi.org/10.1016/j.antiviral.2015.12.006.
26. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82:95–102. https://doi.org/10.1016/j.antiviral.2009.02.198.
27. Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJ, Neyts J. 2016. The viral polymerase inhibitor 7-deaza-2=-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis 10:e0004695. https://doi.org/10.1371/journal.pntd.0004695.
28. Tokunaga T, Yamamoto Y, Sakai M, Tomonaga K, Honda T. 2017. Antiviral activity of favipiravir (T-705) against mammalian and avian borna-viruses. Antiviral Res 143:237–245. https://doi.org/10.1016/j.antiviral.2017.04.018.
29. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981–986. https://doi.org/10.1128/AAC.49.3.981-986.2005.
30. Delang L, Segura Guerrero N, Tas A, Querat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69: 2770–2784. https://doi.org/10.1093/jac/dku209.
31. Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, Furuta Y. 2013. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57:5202–5208. https://doi.org/10.1128/AAC.00649-13.
32. Vanderlinden E, Vrancken B, Van Houdt J, Rajwanshi VK, Gillemot S, Andrei G, Lemey P, Naesens L. 2016. Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 60:6679–6691. https://doi.org/10.1128/AAC.01156-16.
33. Arias A, Thorne L, Goodfellow I. 2014. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife 3:e03679. https://doi.org/10.7554/eLife.03679.
34. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741–3751. https://doi.org/10.1128/JVI.02346-12.
35. de Avila AI, Gallego I, Soria ME, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C. 2016. Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS One 11:e0164691. https://doi.org/10.1371/ journal.pone.0164691.
36. Thorne L, Arias A, Goodfellow I. 2016. Advances toward a norovirus antiviral: from classical inhibitors to lethal mutagenesis. J Infect Dis 213(Suppl 1):S27–S31. https://doi.org/10.1093/infdis/jiv280.
37. de Avila AI, Moreno E, Perales C, Domingo E. 2017. Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus. Virus Res 233:105–112. https://doi.org/10.1016/j.virusres.2017.03.014.
38. Lanciotti RS, Ebel GD, Deubel V, Kerst AJ, Murri S, Meyer R, Bowen M, McKinney N, Morrill WE, Crabtree MB, Kramer LD, Roehrig JT. 2002. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298:96–105. https://doi.org/10.1006/viro.2002.1449.
39. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofura-nosyl 5=-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347. https://doi.org/10.1371/journal.pone.0068347.
40. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 100:7289–7294. https://doi.org/10.1073/pnas.1232294100.
41. Ferrer-Orta C, Sierra M, Agudo R, de la Higuera I, Arias A, Perez-Luque R, Escarmis C, Domingo E, Verdaguer N. 2010. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J Virol 84:6188–6199. https://doi.org/10.1128/JVI.02420-09.
42. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, Christensen AJ, Furuta Y. 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 80:377–379. https://doi.org/10.1016/j.antiviral.2008.07.009.
43. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106 Antimicrob Agents Chemother 53:202–209. https://doi.org/10.1128/AAC.01074-08.
44. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. 2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17–21. https://doi.org/10.1016/j.antiviral.2014.02.014.
45. Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL. 2014. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley fever. PLoS Negl Trop Dis 8:e2790. https://doi.org/10.1371/journal.pntd.0002790.
46. Buys KK, Jung KH, Smee DF, Furuta Y, Gowen BB. 2011. Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir Chem Chemother 21:193–200. https://doi.org/10.3851/IMP1729.
47. Iranzo J, Perales C, Domingo E, Manrubia SC. 2011. Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach. Proc Natl Acad Sci U S A 108:16008–16013. https://doi.org/10.1073/pnas.1110489108.
48. Perales C, Iranzo J, Manrubia SC, Domingo E. 2012. The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol 20:595–603. https://doi.org/10.1016/j.tim.2012.08.010.
49. Merino-Ramos T, Blazquez AB, Escribano-Romero E, Canas-Arranz R, Sobrino F, Saiz JC, Martin-Acebes MA. 2014. Protection of a single dose West Nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus. PLoS One 9:e108056. https://doi.org/10.1371/journal.pone.0108056.
50. Martin-Acebes MA, Saiz JC. 2011. A West Nile virus mutant with increased resistance to acid-induced inactivation. J Gen Virol 92:831–840. https://doi.org/10.1099/vir.0.027185-0.
51. Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, Komar N, Panella NA, Allen BC, Volpe KE, Davis BS, Roehrig JT. 2000. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol 38:4066–4071.
52. Blazquez AB, Saiz JC. 2010. West Nile virus (WNV) transmission routes in the murine model: intrauterine, by breastfeeding and after cannibal ingestion. Virus Res 151:240–243. https://doi.org/10.1016/j.virusres.2010.04.009.
53. Escribano-Romero E, Gamino V, Merino-Ramos T, Blazquez AB, Martin-Acebes MA, de Oya NJ, Gutierrez-Guzman AV, Escribano JM, Hofle U, Saiz JC. 2013. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE). Vaccine 31:4523– 4527. https://doi.org/10.1016/j.vaccine.2013.07.071.
54. Airaksinen A, Pariente N, Menendez-Arias L, Domingo E. 2003. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311:339 –349. https://doi.org/10.1016/S0042-6822(03)00144-2.